Charles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing
21 Febrero 2024 - 7:00AM
Business Wire
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced a strategic agreement with Wheeler Bio, Inc., an antibody
contract development and manufacturing organization (CDMO) focused
on preclinical and early clinical supply of recombinant proteins,
providing clients access to Wheeler’s Portable CMC® (Chemistry,
Manufacturing and Controls) platform. This new alliance provides
early-stage biotechnology companies a unique solution to rapidly
transition from pre-clinical activities to first-in-human clinical
trials.
Combining Charles River’s industry-leading experience in
antibody discovery services, safety, and analytics with Wheeler’s
Portable CMC® platform will accelerate therapeutic discovery to IND
submission timelines. This umbrella offering efficiently connects
the preclinical, clinical manufacturing, and release testing
journeys, significantly reducing the complexity of managing
multiple vendor relationships. Integrating CMC development early in
discovery enables therapeutic developers to collaborate with
experts across the organizations to utilize phase-appropriate
manufacturing and analytics. The services and expertise come
together to provide a single concept-to-commercial offering.
Wheeler’s mission is to solve translational challenges inherent
in advancing from discovery to CMC development and early-clinical
trial material supply. Wheeler’s Portable CMC® is a
validation-ready production process which reduces technical and
regulatory risk. The organization operates the Portable CMC®
platform in Wheeler’s state-of-the-art process development labs in
Oklahoma City, OK, which also houses a CGMP facility-of-the-future
with on-site Charles River RightSource™ quality control testing
labs. There is an additional satellite lab in Waltham, MA featuring
protein sciences and bench scale process capabilities. Wheeler
provides startup biotechs with access to a high quality, agile,
affordable path to clinical supply with thoughtfully designed,
modular work packages featuring Leap-in Transposase® for
pools-based workflow parallelization, standard analytics, and
discrete CMC milestones that align with innovators’ fundraising
milestones.
Approved Quotes
- “We are thrilled to provide Charles River clients with access
to Wheeler’s innovative Portable CMC® platform, which will optimize
their workflows and ultimately bring new treatments to patients
faster.” –Julie Frearson, Corporate Senior Vice President, Chief
Scientific Officer, Charles River
- “Wheeler is excited to expand our relationship with Charles
River and to link with their discovery organization. By integrating
discovery CRO and CDMO workflows, we can speed our clients’ path to
first-in-human trials, thereby achieving clinical decisions faster.
Our combined sales teams look forward to co-promoting these
services for the benefit of our biotech partners and their
pipelines towards clinical impact.” —Jesse McCool, CEO and
Co-Founder, Wheeler Bio
About Charles River Charles River provides essential
products and services to help pharmaceutical and biotechnology
companies, government agencies and leading academic institutions
around the globe accelerate their research and drug development
efforts. Our dedicated employees are focused on providing clients
with exactly what they need to improve and expedite the discovery,
early-stage development and safe manufacture of new therapies for
the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
About Wheeler Bio Wheeler Bio is a biomanufacturing
pioneer, founded by a team of industry experts and strategic
investors who believe a different CDMO model is needed to help
innovators reach their clinical milestones faster. Wheeler’s novel
hub-and-spoke operational model, centered in the biomanufacturing
metro of Oklahoma City, and integrated with biotechs and discovery
CROs, will revolutionize the speed of drug development. Wheeler
Bio’s technology platform, Portable CMC®, simplifies the path
between drug discovery and clinical manufacturing by providing a
new bridge for translating discoveries to first-in-human trials.
Innovators benefit from increased momentum during technology
transfer, shorter timelines, reduced risk, and lower costs.
Additional information can be obtained by visiting wheelerbio.com
or by following Wheeler Bio on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240221892461/en/
Charles River Investor Contact: Todd Spencer Corporate
Vice President, Investor Relations 781.222.6455
todd.spencer@crl.com
Charles River Media Contact: Amy Cianciaruso Corporate
Vice President, Chief Communications Officer 781.222.6168
amy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Charles River Laboratories (NYSE:CRL)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024